Correlation Between Nokia Oyj and Innate Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Nokia Oyj and Innate Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Nokia Oyj and Innate Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Nokia Oyj and Innate Pharma, you can compare the effects of market volatilities on Nokia Oyj and Innate Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Nokia Oyj with a short position of Innate Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Nokia Oyj and Innate Pharma.

Diversification Opportunities for Nokia Oyj and Innate Pharma

0.42
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Nokia and Innate is 0.42. Overlapping area represents the amount of risk that can be diversified away by holding Nokia Oyj and Innate Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Innate Pharma and Nokia Oyj is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Nokia Oyj are associated (or correlated) with Innate Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Innate Pharma has no effect on the direction of Nokia Oyj i.e., Nokia Oyj and Innate Pharma go up and down completely randomly.

Pair Corralation between Nokia Oyj and Innate Pharma

Assuming the 90 days trading horizon Nokia Oyj is expected to generate 0.65 times more return on investment than Innate Pharma. However, Nokia Oyj is 1.55 times less risky than Innate Pharma. It trades about 0.13 of its potential returns per unit of risk. Innate Pharma is currently generating about -0.01 per unit of risk. If you would invest  423.00  in Nokia Oyj on December 30, 2024 and sell it today you would earn a total of  62.00  from holding Nokia Oyj or generate 14.66% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Nokia Oyj  vs.  Innate Pharma

 Performance 
       Timeline  
Nokia Oyj 

Risk-Adjusted Performance

OK

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Nokia Oyj are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Nokia Oyj reported solid returns over the last few months and may actually be approaching a breakup point.
Innate Pharma 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Innate Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong technical indicators, Innate Pharma is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Nokia Oyj and Innate Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Nokia Oyj and Innate Pharma

The main advantage of trading using opposite Nokia Oyj and Innate Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Nokia Oyj position performs unexpectedly, Innate Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Innate Pharma will offset losses from the drop in Innate Pharma's long position.
The idea behind Nokia Oyj and Innate Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Other Complementary Tools

CEOs Directory
Screen CEOs from public companies around the world
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets